Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-6257 in Healthy Subjects
NCT07301333Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in pain comparing HRS-6257 group with placebo group (2 arms). Primary endpoint: Incidence and severity of adverse events at Day 27. Started Dec 2025; status: completed.
02
Drugs
HRS-6257
03
Conditions
pain
Beyond the preview
Go deeper on NCT07301333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07301333.